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This is the ﬁrst case report describing a complete response to bicalutamide withdrawal that lasted for
almost 2 years in a patient with metastatic prostate cancer. An 80-year-old man who had prostate-
speciﬁc antigen (PSA) level elevation (168.1 ng/mL) visited our hospital in February 2010. Bone scin-
tigraphy showed pelvic metastases. We started hormonal therapy with leuprorelin and bicalutamide. The
PSA concentration decreased to <0.1 ng/mL but started increasing again and reached 1.64 ng/mL in
October 2012, at which time bicalutamide administration was discontinued. The PSA concentration
decreased again and has remained below the limit of sensitivity for almost 2 years.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Cancer of the prostate is the most prevalent cancer in American
men. Metastatic prostate cancer is primarily treated by testicular
androgen ablation (medical or surgical). Nonsteroidal anti-
androgens are commonly used with luteinizing hormonee
releasing hormone analogs for metastatic prostate cancer.
Withdrawal responses after estrogenic therapy for breast cancer
were reported in 1986. Withdrawal responses in prostate cancer
patients were initially documented after treatment with ﬂutamide.1
Since then, withdrawal responses after other antiandrogens have
been reported in prostate cancer cases.2
Some cases respond well to antiandrogen withdrawal, with a
>50% decline in prostate-speciﬁc antigen (PSA) level, but the
duration of remission is limited to approximately 6 months.
We report here a patient with metastatic prostate cancer who
had complete remission for almost 2 years after bicalutamide
withdrawal.Case presentation
An 80-year-old man visited our hospital in February 2006 for
further evaluation of PSA level elevation, which was 168.1 ng/mL. ABY-NC-ND license (http://
: þ81-3-3225-1985.
.
Published by Elsevier Inc. All righstony hard nodule was found in the right lobe of the prostate on
digital rectal examination. The patient had hip pain. We strongly
suspected metastatic prostate cancer. We scheduled a prostate
biopsy within a fewweeks, but he experienced an acute myocardial
infarction and was admitted to the cardiovascular department of
our hospital before the biopsy. Magnetic resonance imaging per-
formed during hospitalization showed a gadolinium-enhanced tu-
mor with a low T2 signal in the right lobe of the prostate. Bone
scintigraphy showed metastatic tumors in the hip bone and pubis
(Fig. 1). We made a diagnosis of poorly differentiated prostate
cancer based on a physical examination and imaging test without
the prostate biopsy because of the limitations of the indication.
Hormonal therapy with leuprorelin and bicalutamide was started.
The PSA concentration decreased to <0.1 ng/mL in 3 months, but
started increasing again from the beginning of 2010, and reached
1.64 ng/mL in October 2012. The hip painworsened and the alkaline
phosphatase level rose to 453 IU/L. Bicalutamide administration
was discontinued. The PSA concentration started declining again
after a month, and dropped to <0.01 ng/mL within 3 months. The
pain was resolved and the alkaline phosphatase concentration
decreased to a normal level. The concentration of testosterone
remained under 0.1 ng/mL after bicalutamide withdrawal. The PSA
concentration has remained below the limit of sensitivity till date,
which is almost 2 years (Fig. 2).Discussion
Antiandrogen withdrawal syndrome with ﬂutamide was ﬁrst
reported in 1993.1 Since then, withdrawal responses after other
antiandrogens have been reported in prostate cancer cases.2ts reserved.
Figure 1. Bone scintigraphy and magnetic resonance imaging (MRI). (a) Bone scintigraphy showed metastatic tumors in the hip bone and pubis (black arrow). (b) MRI showed a
gadolinium-enhanced tumor (white arrow) and metastatic bone tumors (black arrow).
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reduce symptoms related to prostate cancer. There are thought to
be many different mechanisms involved in the antiandrogen
withdrawal syndrome. These include mutation of the androgen
receptor gene and its coregulatory proteins and activation of the
signal transduction pathways that may not involve the androgen
receptor pathway.3 It is also possible that no single mechanism is
utilized in each case.
The response rate of antiandrogen withdrawal, which is deﬁned
as more than a 50% decline in the PSA level, is about 30%. A
declining PSA level is seen within 4-8 weeks after discontinuation
of antiandrogens. The duration of the response to antiandrogen
withdrawal is limited to approximately 3-6 months. It was reported
in 2008 that a lower (<10 ng/mL) baseline PSA level, no metastasis,
and longer duration of antiandrogen use were predictors of pro-
longed antiandrogen withdrawal.4 There have been reports of a
sustained decline in PSA level <1 ng/mL for 1-2 years after anti-
androgen withdrawal. However, there have been no reports of
complete remission of PSA level, that is, <0.01 ng/mL, for several
years after bicalutamide withdrawal. In the present case, we found
the PSA level had remained below the limit of sensitivity for almostFigure 2. Clinical course and changes in prostate-speciﬁc antigen (PSA) and alkaline
phosphatase (ALP) concentrations. The PSA and ALP concentrations declined after
bicalutamide withdrawal. The PSA concentration was sustained under 0.01 ng/mL, and
the ALP concentration was within the normal range for almost 2 years.2 years after bicalutamide withdrawal. We believe this to be a very
rare case.
It remains uncertain whether responders of androgen with-
drawal have a better prognosis. Antiandrogen withdrawal syn-
drome is not included in therapeutic options for castration-
resistant prostate cancer in the 2014 European Association of
Urology guidelines.5 However, in Japan the only therapy currently
available for metastatic castration-resistant prostate cancer is
docetaxel-prednisolone therapy, which often has strong adverse
effects. Our patient has maintained an excellent physical condition
for almost 2 years without such side effects. Bicalutamide with-
drawal clearly contributed to an improvement of the quality of life
of this patient.
Conclusion
We have described a patient whose PSA level remained below
the limit of sensitivity for almost 2 years after bicalutamide with-
drawal. Further study of the antiandrogenwithdrawal response rate
and the duration of PSA decline for each drug withdrawal is needed,
which may contribute information concerning the choice of ﬁrst-
line antiandrogen drugs.
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Informed consent was obtained from the patient for publication
of this case report and any accompanying images.
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